Clinical Trial Update: Study to Compare Efficacy, Safety, and Immunogenicity of LUBT010 (Proposed Ranibizumab Biosimilar) and Lucentis® in Patients With Neovascular AMD [Phase 3]

View source ↗

Summary

Phase 3 trial comparing LUBT010, a proposed ranibizumab biosimilar, with Lucentis for neovascular age-related macular degeneration has completed and results hav…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration

Drugs mentioned

• LUBT010 (ranibizumab)
• Lucentis (ranibizumab)

Snippet

Sponsor: Lupin Ltd. | Conditions: Neovascular Age-related Macular Degeneration | Phase 3 | Status: COMPLETED | Results posted: 2026-01-06